Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 14

1.

Development and evaluation of a cetuximab-based imaging probe to target EGFR and EGFRvIII.

Aerts HJ, Dubois L, Hackeng TM, Straathof R, Chiu RK, Lieuwes NG, Jutten B, Weppler SA, Lammering G, Wouters BG, Lambin P.

Radiother Oncol. 2007 Jun;83(3):326-32. Epub 2007 May 24.

PMID:
17531336
2.

Sensitivity and specificity of fluorescent immunoguided neoplasm detection in head and neck cancer xenografts.

Kulbersh BD, Duncan RD, Magnuson JS, Skipper JB, Zinn K, Rosenthal EL.

Arch Otolaryngol Head Neck Surg. 2007 May;133(5):511-5.

PMID:
17520766
3.

PET detection of epidermal growth factor receptor in colorectal cancer: a real predictor of response to cetuximab treatment?

Pantaleo MA, Fanti S, Lollini PL, Boschi S, Biasco G.

Eur J Nucl Med Mol Imaging. 2007 Sep;34(9):1510-1. Epub 2007 Apr 20. No abstract available.

PMID:
17447062
4.

Use of fluorescent labeled anti-epidermal growth factor receptor antibody to image head and neck squamous cell carcinoma xenografts.

Rosenthal EL, Kulbersh BD, King T, Chaudhuri TR, Zinn KR.

Mol Cancer Ther. 2007 Apr;6(4):1230-8.

5.

Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody.

Cai W, Chen K, He L, Cao Q, Koong A, Chen X.

Eur J Nucl Med Mol Imaging. 2007 Jun;34(6):850-8. Epub 2007 Jan 30.

PMID:
17262214
6.

In vivo detection of head and neck cancer orthotopic xenografts by immunofluorescence.

Rosenthal EL, Kulbersh BD, Duncan RD, Zhang W, Magnuson JS, Carroll WR, Zinn K.

Laryngoscope. 2006 Sep;116(9):1636-41.

PMID:
16954995
7.

Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.

Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, Gooding WE, Furnari FB, Grandis JR.

Clin Cancer Res. 2006 Sep 1;12(17):5064-73.

8.

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK.

N Engl J Med. 2006 Feb 9;354(6):567-78.

9.

Radiation dosimetry of 99mTc-labeled C225 in patients with squamous cell carcinoma of the head and neck.

Schechter NR, Wendt RE 3rd, Yang DJ, Azhdarinia A, Erwin WD, Stachowiak AM, Broemeling LD, Kim EE, Cox JD, Podoloff DA, Ang KK.

J Nucl Med. 2004 Oct;45(10):1683-7.

10.

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.

Xiong HQ, Rosenberg A, LoBuglio A, Schmidt W, Wolff RA, Deutsch J, Needle M, Abbruzzese JL.

J Clin Oncol. 2004 Jul 1;22(13):2610-6.

PMID:
15226328
11.

Recent advances of molecular targeted agents: opportunities for imaging.

Dancey JE.

Cancer Biol Ther. 2003 Nov-Dec;2(6):601-9. Review.

PMID:
14688462
12.

Targeting epidermal growth factor receptor--are we missing the mark?

Dancey JE, Freidlin B.

Lancet. 2003 Jul 5;362(9377):62-4. Review.

PMID:
12853203
13.

Assessment of epidermal growth factor receptor with 99mTc-ethylenedicysteine-C225 monoclonal antibody.

Schechter NR, Yang DJ, Azhdarinia A, Kohanim S, Wendt R 3rd, Oh CS, Hu M, Yu DF, Bryant J, Ang KK, Forster KM, Kim EE, Podoloff DA.

Anticancer Drugs. 2003 Jan;14(1):49-56.

PMID:
12544258
14.

Supplemental Content

Support Center